MAPK3 and colorectal cancer: The findings were in line with the effect of EGCG on colorectal-cancer HT-29 cells, which inhibited cell proliferation in a dose-dependent manner, by inhibiting Akt, ERK1/2, or alternative p38MAPK activity [20].